Human IFN-α Antibody - Rontalizumab Biosimilar

Human IgG1 - CAS #948570-30-7 

ABOUT

Anti-human IFN alpha - Rontalizumab biosimilar - CAS #948570-30-7

Anti-hIFN-α-hIgG1 is a biosimilar antibody of Rontalizumab, a therapeutic antibody that targets interferon alpha (IFN-α). This monoclonal antibody (mAb) blocks the interaction of IFN-α with its receptor. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE).

More details More details

 

Anti-hIFN-α-hIgG1 comprises the variable region of Rontalizumab and the human IgG1 constant region of Rontalizumab with high effector functions.

This antibody can be used with HEK-Blue™ IFN-α/β cells for screening and neutralization assays to block recombinant human IFN-α-induced signaling(see figure).

Key features

  • Potent and specific neutralization activity against hIFN-α2
  • Reacts with hIFN-α1, hIFN-α2, hIFN-α5, hIFN-α8, hIFN-α14, hIFN-α16, hIFN-α17, and hIFN-α21
  • Weakly reacts with hIFN-α4 and IFN-α10
  • Does not react with hIFN-α6 or hIFN-α7
  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined using the EndotoxDetect™ assay.

All InvivoGen products are for internal research use only, and not for human or veterinary use.

Binding of Anti-hIFN-α Rontalizumab
Binding of Anti-hIFN-α Rontalizumab

SPECIFICATIONS

Specifications

Target

IFN-α

Target species

Human

Crossreactivity

Reacts with human IFN-α1, IFN-α2, IFN-α5, IFN-α8, IFN-α14, IFN-α16, IFN-α17 and IFN-α21. Very weakly reacts with human IFN-α4 and IFN-α10. It does not react with IFN-α6 or IFN-α7.

Applications

Blocking & Neutralization

Species
Human
Isotype
hIgG1
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Rontalizumab
CAS number
948570-30-7
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Sterility

0.2 µm filtration

Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA, Fc effector function analysis

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIFN-α-hIgG1
  • Cat code: 
    hifna-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Rontalizumab background

Rontalizumab (aka rhuMAb interferon-alpha) is a therapeutic, humanized monoclonal antibody (mAb) that targets the human interferon-alpha (IFN-α) cytokine subtypes [1, 2]. By binding to IFN-α, Rontalizumab prevents it from interacting with its receptor (IFNAR) on the surface of immune cells, thus inhibiting the downstream inflammatory response. Rontalizumab has been clinically evaluated as an immunosuppressive agent for the treatment of systemic lupus erythematosus (SLE) [1-3]. 

 

References:

1. McBride JM, et al. 2012. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study. Arthritis Rheum. 64(11):3666-76.
2. Kalunian KC, et al., 2016. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE). Ann Rheum Dis. (2016) 75:196–202.
3. Jones, S.A. and Morand, E.F., 2024. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned. Drugs. 84(6):625-635.

You may also need

Citations

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?